BAX NYSE
Baxter International Inc.
1W: +1.6%
1M: +6.0%
3M: +0.6%
YTD: +27.9%
1Y: +8.4%
3Y: -19.4%
5Y: -65.5%
$24.92
-0.37 (-1.46%)
Weekly Expected Move ±4.1%
$23
$24
$25
$26
$27
Credit Risk of going bust: higher than 64% of companies Debt: 42.9% of company value Bonds: $263.3M held by 339 funds, 111 bp over Treasuries → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.45 (down 94%), Baxter International Inc. would be worth roughly what it owes.
Total debt $9.67B against a stock market value of $12.88B.
Distance to default 3.87 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $5.15B (short-term plus half of long-term), stock volatility 44.0%; Altman Z 2.30. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.45 (down 94%), Baxter International Inc. would be worth roughly what it owes.
Total debt $9.67B against a stock market value of $12.88B.
Distance to default 3.87 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $5.15B (short-term plus half of long-term), stock volatility 44.0%; Altman Z 2.30. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
23 relationships23
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-09-02
Earliest Filing
2025-02-03
Latest Filing
acquirer: 15
target: 6
investor: 1
partner: 1
Counterparties (Filed by BAX)
23 relationshipsCompanies named in BAX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Spruce Bidco I, Inc. | — | acquirer | Acquired Vantive Health LLC and related entities from Baxter International Inc. | 2025-02-03 | View |
| Spruce Bidco II, Inc. | — | acquirer | Acquired Vantive Health LLC and related entities from Baxter International Inc. | 2025-02-03 | View |
| Spruce Bidco I Limited | — | acquirer | Acquired Vantive Health LLC and related entities from Baxter International Inc. | 2025-02-03 | View |
| CP Spruce Holdings, S.C.Sp | — | acquirer | Acquired Vantive Health LLC and related entities from Baxter International Inc. | 2025-02-03 | View |
| Spruce Bidco I, Inc. | — | acquirer | Buyer in the acquisition of Baxter's renal care and acute therapies business | 2024-08-13 | View |
| Spruce Bidco II, Inc. | — | acquirer | Buyer in the acquisition of Baxter's renal care and acute therapies business | 2024-08-13 | View |
| Spruce Bidco I Limited | — | acquirer | Buyer in the acquisition of Baxter's renal care and acute therapies business | 2024-08-13 | View |
| CP Spruce Holdings, S.C.Sp | — | acquirer | Buyer in the acquisition of Baxter's renal care and acute therapies business | 2024-08-13 | View |
| CP VIII Spruce GP S.à r.l. | — | acquirer | Managing general partner representing the Buyer entities | 2024-08-13 | View |
| Carlyle | CGABL | investor | Global investment firm managing the funds affiliated with the Buyer | 2024-08-13 | View |
| Bamboo US BidCo LLC | — | acquirer | Acquired Baxter Pharmaceutical Solutions LLC and Baxter Oncology GmbH for $4.25 billion | 2023-10-02 | View |
| Bamboo BidCo GmbH | — | acquirer | Acquired Baxter Pharmaceutical Solutions LLC and Baxter Oncology GmbH for $4.25 billion | 2023-10-02 | View |
| Baxter Healthcare Corporation | BAX | target | Seller of Baxter Pharmaceutical Solutions LLC interests | 2023-10-02 | View |
| Baxter Deutschland Holding GmbH | BAX | target | Seller of Baxter Oncology GmbH interests | 2023-10-02 | View |
| Gambro Dialysatoren GmbH | — | target | Seller of Baxter Oncology GmbH interests | 2023-10-02 | View |
| Bamboo US BidCo LLC | — | acquirer | Acquired Baxter Pharmaceutical Solutions LLC and Baxter Oncology GmbH for $4.25 billion | 2023-05-09 | View |
| Blitz 23-317 GmbH | — | acquirer | Acquired Baxter Pharmaceutical Solutions LLC and Baxter Oncology GmbH for $4.25 billion | 2023-05-09 | View |
| Baxter International Inc. | BAX | acquirer | Acquired Hill-Rom Holdings, Inc. in a merger completed on December 13, 2021. | 2021-12-13 | View |
| Hill-Rom Holdings, Inc. | HRL | target | Target company acquired by Baxter International Inc. in a merger completed on December 13, 2021. | 2021-12-13 | View |
| Bel Air Subsidiary, Inc. | — | partner | Wholly owned subsidiary of Baxter International Inc. that merged with Hill-Rom Holdings, Inc. | 2021-12-13 | View |
| Bardy Diagnostics, Inc. | — | acquirer | Acquired by Hill-Rom Holdings, Inc. for $434.2 million in August 2021. | 2021-12-13 | View |
| Hill-Rom Holdings, Inc. | — | target | Target company in the proposed Merger | 2021-12-02 | View |
| Hill-Rom Holdings, Inc. | HRL | target | Target company in a merger agreement to be acquired by Baxter International Inc. | 2021-09-02 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-19 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-08-18 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-08-04 | Other Events; Exhibits | View | |
| 2026-08-04 | Officer/Director Change | View | |
| 2026-07-30 | Earnings Release; Other Events; Exhibits | View | |
| 2026-07-14 | Regulation FD; Exhibits | View | |
| 2026-05-08 | Officer/Director Change; Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-04-30 | Earnings Release; Other Events; Exhibits | View | |
| 2026-03-19 | Regulation FD; Exhibits | View | |
| 2026-03-16 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2026-02-12 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-12-22 | Other Events | View | |
| 2025-12-04 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Creation of | Agreement | View |
| 2025-11-25 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-11-19 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-19 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-12 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-10-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-21 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-07-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR